GENEDRIVE PLC — Share Issue/Capital Change 2018

Nov 19, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8101H

Genedrive PLC

19 November 2018

19 November 2018

genedrive plc ("genedrive" or the "Company")

Posting of Shareholder Circular

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, confirms that further to the announcement made on 16 November 2018, a Circular has been published and will be posted to shareholders today in relation to the proposed Placing of 15,217,391 new Ordinary Shares at 23 pence per share raising £3.5 million, the issue of £2.5 million convertible Loan Notes and a broker option of up to £0.5 million through the issue of up to 2,173,913 additional new Ordinary Shares. The circular contains the notice convening the General Meeting to be held at the offices of the Company: The Incubator Building, 48 Grafton Street, Manchester, M13 9XX at 12 noon on 7 December 2018.

A copy of the Circular will shortly be available on the Company's website at the following URL: www.genedriveplc.com.

-  Ends -

For further details please contact:

genedrive plc David Budd: CEO Matthew Fowler: CFO		+44 (0)161 989 0245
Peel Hunt LLP James Steel Oliver Jackson		+44 (0)207 418 8900
Stanford Capital Partners Limited Patrick Claridge		+44 (0)203 815 8880
John Howes
Consilium Strategic Communications Chris Gardner Matthew Neal Laura Thornton		+44 (0) 203 709 5700 genedrive@consilium-comms.com

Notes to Editors

About genedrive

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com and www.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CIREKLFFVFFLFBZ